Skip to main content
VRDN
NASDAQ Life Sciences

Major Shareholder Fairmount Funds Buys $20M in Recent Public Offering, Increasing Stake to 14.04%

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$18.06
Mkt Cap
$1.756B
52W Low
$12.07
52W High
$34.29
52W Position info
50% above low
Off High info
47% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

VRDN sits 50% above its 52-week low of $12.07.

Summary

Fairmount Funds Management LLC, a 10% owner, invested $20 million in Viridian Therapeutics' recent public offering, increasing its beneficial ownership to 14.04% of outstanding common stock.


Key Events · Ownership and Investor Activity · VRDN

  • Major Shareholder Increases Stake

    Fairmount Funds Management LLC, a 10% owner, purchased 1,176,470 shares of common stock for $19,999,990.00.

  • Participation in Public Offering

    The shares were acquired on May 11, 2026, as part of an underwritten public offering, priced at $17.00 per share.

  • New Ownership Percentage

    Fairmount Funds Management LLC now beneficially owns 17,201,800 shares, representing 14.04% of the company's common stock.

  • 60-Day Lock-Up Agreement

    The fund entered into a customary 60-day lock-up agreement, restricting sales of shares without underwriter consent.


Analysis · VRDN · Life Sciences

Fairmount Funds Management LLC, a significant institutional investor, purchased nearly $20 million worth of Viridian Therapeutics common stock in the company's recent public offering. This substantial investment, representing over 1% of the company's market capitalization, demonstrates strong conviction from a major shareholder, especially following the recent positive clinical data and capital raise. The purchase was made at $17.00 per share, and Fairmount has agreed to a 60-day lock-up period, further signaling a commitment to their investment.

How filings like this one have moved

In the 30 days to Nov 4, 2026, 41.6% of the 1192 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.37%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, VRDN was trading at $18.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $12.07 to $34.29. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VRDN - Latest Insights

VRDN
Nov 04, 2026, 7:11 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $27.75
Real-time Price: $29.72 info
Change: +$1.97 (+7%) info
Market Cap: $3.292B info
VRDN
Nov 04, 2026, 7:01 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $27.09
Real-time Price: $29.72 info
Change: +$2.63 (+10%) info
Market Cap: $3.292B info
VRDN
Aug 06, 2026, 7:31 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $20.87
Real-time Price: $29.72 info
Change: +$8.85 (+42%) info
Market Cap: $3.292B info
VRDN
Aug 06, 2026, 7:19 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $21.50
Real-time Price: $29.72 info
Change: +$8.22 (+38%) info
Market Cap: $3.292B info
VRDN
Aug 06, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $20.81
Real-time Price: $29.72 info
Change: +$8.91 (+43%) info
Market Cap: $3.292B info